Brain health screening-Shenzhen New Frontier United Family Hospital

Brain health screening

1. Alzheimer's Disease (AD)

What is Alzheimer's Disease (AD)?

It is a progressive neurodegenerative disease known as the "thief of memory". It damages brain cells and causes cognitive decline. In the advanced stage, patients almost completely lose their memory, being unable to recognize relatives, recall the past, or understand the current situation. Their disorientation worsens—they may even fail to recognize their own names or the environment they are in. Meanwhile, agnosia (inability to identify common objects) and apraxia (loss of the ability to perform simple movements) make it impossible for patients to carry out basic activities such as getting dressed and eating.

Early Symptoms of Alzheimer's Disease

1. Memory decline

2. Difficulty in executing familiar activities

3. Speaks incoherently

4. Decreased judgment

5. Inaccurate timing and location

6. Failure to handle affairs on time

7. Putting things in the wrong place

8. Changes in emotions and behavior

9. Difficulty understanding visual spatial information

10. Become withdrawn

Global and Chinese Prevalence

· Global AD The number of patients exceeds 50 million, with China accounting for over 10 million.

· 80% of patients are diagnosed in the middle or late stages, missing the optimal intervention window.

· It is recommended to start regular brain health screening at the age of 45 to detect risks early and prevent cognitive decline progression through early intervention.

2. Brain Health Examination Technologies and Methods

1. Non-Invasive and Accurate EEG Screening for Cognitive Decline

· Technical Basis: Electroencephalography (EEG) is the only technology that can directly and non-invasively record the electrical activity of neurons.

· Advantages: It captures transient changes in brain function at the millisecond level, enabling the identification of abnormal neural electrical activity in the early stage of Alzheimer's Disease. With high sensitivity, non-invasiveness, and convenience, it is a powerful tool for the early identification and long-term monitoring of AD.

2. Accurate and Non-Invasive Neuromodulation Technology

· Technical Basis: Transcranial Magnetic Stimulation (TMS) uses pulsed magnetic fields to directly affect brain metabolism and neural electrical activity.

· Application Scope: It can be used in the treatment of cognitive impairment, sleep disorders, Parkinson's Disease, epilepsy, etc.

· Advantages: It can easily achieve deep brain stimulation, causes minimal discomfort, and is non-invasive.

3. Hierarchical Screening and Intervention System for Brain Health

The latent period of AD can be as long as 10-20 years. Early brain health screening can detect risks in a timely manner, avoiding the loss of the optimal intervention window for targeted drugs (such as lecanemab).

Stage	Examination/Intervention Method	Specific Content
Non-Invasive Initial Screening	AI-Enhanced EEG Intelligent Analysis	Highly sensitive, non-invasive, and convenient. It records neuronal electrical activity via 64-channel EEG and intelligently assesses the risk level of cognitive decline.
Confirmatory Diagnosis	Biomarker and Functional Imaging Examinations	Detects biomarkers including P-Tau217, P-Tau181, Aβ-42, Aβ-40, Aβ-42/Aβ-40 ratio, and microtubule-associated Tau protein markers. Combined with 3.0T MRI, it analyzes structural changes in the brain related to cognitive decline.
Etiological Typing	Comprehensive Examination to Analyze Factors Affecting Cognitive Decline	Conducts 12 specialized tests covering inflammation, toxins, metabolism, etc., to trace the pathogenic mechanism and achieve etiological typing.
Personalized Intervention	Targeted Diagnosis and Treatment Plan	1. Neuromodulation: Develops personalized transcranial magnetic stimulation treatment plans based on EEG results, simultaneously treating comorbid depression/insomnia to achieve neuro-psychological collaborative recovery. 2. Pharmacological Treatment: Provides access to new and effective drugs such as lecanemab and donanemab. 3. Metabolic Intervention: Customizes dietary plans to regulate brain energy metabolism and reduce neuroinflammatory factors.